It is used (particularly intravenously, as the lactate) for the short-term management of severe heart failure. Milrinone inhibits the action of phosphodiesterase-3 preventing degradation of cAMP. The corresponding increase in cAMP levels leads to increased activation of protein kinase A. It is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity.
Narimatsu E, et al. Milrinone, a phosphodiesterase III inhibitor, antagonizes the neuromuscular blocking effect of a non-depolarizing muscle relaxant in vitro.Res. Commun. Mol. Pathol. Pharmacol.,1999,104(2), 219-228.
Cheung P, et al. Milrinone, a selective phosphodiesterase 3 inhibitor, stimulates lipolysis, endogenous glucose production, and insulin secretion.Metabolism: clinical and experimental.,2003,52(11), 1496-1500.
Hazard Statements: H300-H311-H331
Fatal if swallowed. Toxic in contact with skin. Toxic if inhaled.
Precautionary Statements: P261-P280h-P301+P310a-P304+P340-P405-P501a
Avoid breathing dust/fume/gas/mist/vapours/spray. Wear protective gloves/clothing. IF SWALLOWED: IF INHALED: Remove to fresh air and keep at rest in a position comfortable for breathing. Store locked up. Dispose of contents/container in accordance with local/regional/national/international regulations.